Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., ...More

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.90, no.4, pp.458-468, 2019 (SCI-Expanded) identifier identifier identifier


Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.